Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis.
ALS
RNA-seq
amyotrophic lateral sclerosis
biomarker
non-coding RNA
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
ppublish
Résumé
Objective biomarkers for the clinically heterogeneous adult-onset neurodegenerative disorder amyotrophic lateral sclerosis are crucial to facilitate assessing emerging therapeutics and improve the diagnostic pathway in what is a clinically heterogeneous syndrome. With non-coding RNA transcripts including microRNA, piwi-RNA and transfer RNA present in human biofluids, we sought to identify whether non-coding RNA in serum could be biomarkers for amyotrophic lateral sclerosis. Serum samples from our Oxford Study for Biomarkers in motor neurone disease/amyotrophic lateral sclerosis discovery cohort of amyotrophic lateral sclerosis patients (n = 48), disease mimics (n = 16) and age- and sex-matched healthy controls (n = 24) were profiled for non-coding RNA expression using RNA-sequencing, which showed a wide range of non-coding RNA to be dysregulated. We confirmed significant alterations with reverse transcription-quantitative PCR in the expression of hsa-miR-16-5p, hsa-miR-21-5p, hsa-miR-92a-3p, hsa-piR-33151, TRV-AAC4-1.1 and TRA-AGC6-1.1. Furthermore, hsa-miR-206, a previously identified amyotrophic lateral sclerosis biomarker, showed a binary-like pattern of expression in our samples. Using the expression of these non-coding RNA, we were able to discriminate amyotrophic lateral sclerosis samples from healthy controls in our discovery cohort using a random forest analysis with 93.7% accuracy with promise in predicting progression rate of patients. Importantly, cross-validation of this novel signature using a new geographically distinct cohort of samples from the United Kingdom and Germany with both amyotrophic lateral sclerosis and control samples (n = 156) yielded an accuracy of 73.9%. The high prediction accuracy of this non-coding RNA-based biomarker signature, even across heterogeneous cohorts, demonstrates the strength of our approach as a novel platform to identify and stratify amyotrophic lateral sclerosis patients.
Identifiants
pubmed: 32613197
doi: 10.1093/braincomms/fcaa053
pmc: PMC7329382
mid: EMS86669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
fcaa053Subventions
Organisme : Motor Neurone Disease Association
ID : TURNER/OCT18/989-797
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : HAFEZPARAST/APR15/836-791
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : HAFEZPARAST/APR18/861-791
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K01014X/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : MALASPINA/APR13/817-791
Pays : United Kingdom
Déclaration de conflit d'intérêts
Competing Interests The authors report no competing interests.
Références
Environ Health Prev Med. 2014 Nov;19(6):452-8
pubmed: 25150707
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2010 Apr 2;285(14):10959-68
pubmed: 20129916
RNA Biol. 2018;15(8):1133-1145
pubmed: 30223713
Cancer Prev Res (Phila). 2012 Mar;5(3):492-497
pubmed: 22158052
PLoS Genet. 2011 Aug;7(8):e1002207
pubmed: 21852951
Neurobiol Aging. 2017 Jul;55:123-131
pubmed: 28454844
PLoS One. 2011;6(8):e23423
pubmed: 21853131
J Neurotrauma. 2013 Aug 1;30(15):1349-60
pubmed: 23647386
Nucleic Acids Res. 2011 Nov;39(21):e141
pubmed: 21890899
J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1190-1191
pubmed: 31243045
BMC Genomics. 2019 Jun 3;20(1):446
pubmed: 31159762
Trends Mol Med. 2017 Nov;23(11):989-1001
pubmed: 28988850
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Science. 2009 Dec 11;326(5959):1549-54
pubmed: 20007902
Bioinformatics. 2008 Jul 1;24(13):i390-8
pubmed: 18586739
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Sci Rep. 2016 Jun 20;6:28006
pubmed: 27320175
BMC Med Genomics. 2015 Jul 01;8:35
pubmed: 26130076
Sci Rep. 2018 Feb 21;8(1):3401
pubmed: 29467498
Br J Cancer. 2012 Dec 4;107(12):1987-96
pubmed: 23169280
Clin Chem Lab Med. 2006;44(3):311-6
pubmed: 16519604
RNA Biol. 2018 Feb 1;15(2):242-250
pubmed: 29219730
Sci Rep. 2017 Aug 25;7(1):9538
pubmed: 28842714
J Extracell Vesicles. 2014 Mar 26;3:
pubmed: 24683445
Oncotarget. 2014 Oct 30;5(20):9901-10
pubmed: 25313140
Front Immunol. 2018 Feb 05;8:1977
pubmed: 29459855
FEBS J. 2010 Oct;277(20):4299-307
pubmed: 20840605
Front Neurol. 2019 Mar 07;10:186
pubmed: 30899244
PLoS One. 2014 Feb 20;9(2):e89065
pubmed: 24586506
Neurobiol Aging. 2018 Apr;64:123-138
pubmed: 29458840
J Neurol Sci. 2016 Sep 15;368:19-24
pubmed: 27538595
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
Biol Methods Protoc. 2019 Jun 25;4(1):bpz006
pubmed: 32395624
RNA Biol. 2020 Jan;17(1):75-86
pubmed: 31559901
Lancet. 2011 Mar 12;377(9769):942-55
pubmed: 21296405
PLoS One. 2015 May 05;10(5):e0126049
pubmed: 25942392
Biomed Res Int. 2017;2017:8361237
pubmed: 29214178
Neurobiol Dis. 2013 Jan;49:107-17
pubmed: 22975021
Brain. 2013 Aug;136(Pt 8):2359-68
pubmed: 23824486
Cell Mol Neurobiol. 2013 Jul;33(5):601-13
pubmed: 23633081
Lancet Neurol. 2009 Jan;8(1):94-109
pubmed: 19081518
Anticancer Res. 2016 Dec;36(12):6419-6423
pubmed: 27919963
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
J Cell Biol. 2009 Apr 6;185(1):35-42
pubmed: 19332886
Mol Cancer. 2010 Jul 27;9:198
pubmed: 20663213
Front Neurosci. 2018 Jan 09;11:731
pubmed: 29375285
Int J Mol Sci. 2018 Feb 08;19(2):
pubmed: 29419808
Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1019-1028
pubmed: 29976566